Abraxane meets endpoint in first-line metastatic melanoma

Celgene Corp. (NASDAQ:CELG) said Abraxane nab-paclitaxel met the primary endpoint of

Read the full 113 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE